February 24, 2009 - Researchers are testing the use of positron emission tomography (PET) for dose painting, but have found the technique is limited by PET’s spatial resolution, according to researchers from the Catholic University of Louvain, Brussels, Belgium (Radiother. Oncol. doi: 10.1016/j.radonc.2008.11.014).

The theory is to use PET with a radiotherapy plan that takes account of tumor physiology, and to use PET to "paint" the dose to regions of intense activity or radiation resistance. PET is used in combination with intensity-modulated radiotherapy (IMRT) with an appropriate functional imaging modality.

The use of PET for dose painting relies on a perfect correlation between the observed PET signal and the underlying biology of interest. To test this, Nicolas Christian and colleagues imaged 15 tumor-bearing mice with PET following injection of the radiotracer 2-fluoro-2-deoxyglucose (18F-FDG). The mice were also imaged with MRI and then assessed using autoradiography.

The PET and autoradiography images however did not always match, particularly in tumor sub-volumes with high 18F-FDG-activity. This mismatch is significant because a biological image-guided IMRT plan would most likely increase the dose to these sites. The larger the tumor volume and the lower the activity threshold, then the better the match.

"Unfortunately, we do not yet have access to spatial image resolution that is good enough to be able to visualize what is going on at the microscopic level. We may make fairly large mistakes in the dose distribution by relying on what we see on the PET," said Vincent Grégoire, professor in radiation oncology at the Catholic University of Louvain and corresponding author for the paper.

Grégoire noted that if a PET system with a higher resolution were developed, the technique may be viable. The researchers are instead examining whether alternative radioisotope tracers could provide a better way of finding specific sites in the tumor where the dose should be increased, such as clusters of hypoxic cells. The researchers still want to investigate the concept of PET-based dose painting.

Source: Medical Physics Web

For more information: medicalphysicsweb.org


Related Content

News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Radiation Oncology

Jan. 8, 2026 — RefleXion Medical, an external-beam theranostic oncology company, has announced the U.S. Food and Drug ...

Time January 13, 2026
arrow
News | Radiopharmaceuticals and Tracers

Nov. 18, 2025 — Siemens Healthineers positron emission tomography (PET) radiopharmaceutical companies PETNET Solutions ...

Time November 18, 2025
arrow
News | Radiology Imaging | UC San Diego Health

Oct. 16, 2025 — A strategic collaboration between UC San Diego Health and GE HealthCare will focus on bringing advanced ...

Time October 20, 2025
arrow
News | Radiopharmaceuticals and Tracers

Sept. 20, 2025 — A promising new PET tracer can visualize a protein that is commonly overexpressed in triple-negative ...

Time September 18, 2025
arrow
News | Radiopharmaceuticals and Tracers

Sept. 11, 2025 — A new PET tracer can provide insights into how spinal cord injuries affect not only the spinal cord ...

Time September 12, 2025
arrow
News | Artificial Intelligence

July 22, 2025 — GE HealthCare has topped a U.S. Food and Drug Administration (FDA) list of AI-enabled medical device ...

Time July 23, 2025
arrow
News | PET Imaging

May 30, 2025 — GE HealthCare recently announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) ...

Time May 30, 2025
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
Subscribe Now